Abiomed Readies New Products In Wake Of Negative FDA Panel Vote
This article was originally published in The Gray Sheet
Executive Summary
Abiomed has commitments from several major clinical centers to conduct trials for its Recover 2.5 and 5.0 second-generation cardiac micropumps, following investigational device exemption submissions to FDA